The global rat model market is growing at an impressive CAGR of 9.9% during the forecast period and the revenue is estimated to grow approximately $727.45 million by 2022. There has been a rise in the advancements in the gene editing tools, which is expected to be triggering the growth of global rat model market. Steady increase in the number of neurodegenerative, immunology and oncology disorders is anticipated to propel the growth of global rate model market in the next few years.
Governments across the globe are also investing in the research and development for improved facilities for developing a universal protocol system and also a standard methodology to experiment with the rat model. This will further help the global rat model market to increase its revenue during the forecast period.
As compared to the other rodents, rats provide numerous advantages for the pre-clinical research and analysis. Some of the benefits of rats are convenient physiology monitoring, easy expansion in the embryo-derived cells, and higher learning capacity. All these aforementioned characteristics help in cerebral research and behavior analysis. Further, increasing preference for personalization of medicine that requires personalization of human rat models will also augment the growth of the market in the future. Moreover, technological advancement in the bioinformatics that help to develop software and other tools to analyze the raw data acquired after the pre-clinical research with the help of rat model will open new growth opportunities and help to increase the revenue of the global rat model market during the forecast period of 2016-2022.
The global rat model market growth will slow down during the forecast period due to presence of effective alternatives model including marmosets, macaques, C.elegans and zebrafish that are increasingly used in the pre-clinical research and testing. Furthermore, stringent regulation and ethical laws regarding the use of animals in the clinical research would also impede the growth of the global rat model market.
Market segmentation Insights
Rat model market is segmented based on technology, type, application, and service.
In terms of application, the global rat model market is segmented into CNS, oncology, toxicology, immunology and other applications. Growing demand to develop new transgenic prognosis methods and increasing number of cancer patients globally will results in the oncology segment to grow faster during the forecast period.
On the basis of type, the global rat model market is characterized as outbred, inbred, knockout, immunodeficient, conditioned rats, and hybrids.
The technology segment, within the global rat model market is further categorized into microinjection, embryonic stem cells, nuclear transferase technology and others. Increasing research in the stem cell technology is expected to result in the growth of the stem cell segment, with the technology segment market to account for maximum market share during the forecast period.
In terms of service, the global rat model market is segmented into breeding, cryopreservation, genetic-testing, rederivation, and quarantine and others.
Geographically, the market is segmented into Asia Pacific, North America, Europe, Middle East and Africa, and Latin America. North America region had the maximum share in terms of revenue in the global rat model market in the year 2014. This can be attributed to large pool of companies and CROs operations in the region and revamped capital plans by the NF for patented study.
As a result of research promotion by the European Union and government initiatives for improved treatment of the chronic diseases, Europe has accounted for the second highest market share in terms of revenue in the year 2014.
Owing to improving healthcare policies and infrastructure, the Asia Pacific region is expected to witness a significant growth rate during the forecast period. Moreover, favorable government policies and reimbursement plans given to the research and examination in the region will have a positive impact on the rat model market; thereby increasing the region’s market share and revenue. The rat model market in China is a lucrative sector due to numerous reasons, including less stringent regulation regarding animal safety with increasing research and development. This will further drive the growth of global rat model market in the Asia Pacific region.
The key companies in rat model market include Avastus, Biobserve GmbH, Biomedical Research Models, Inc., Charles River Laboratories, Taconic Biosciences, Inc., Harlan Laboratories, Inc., GenOway S.A., TransViragen, Inc., Janvier Labs, Biobserve GmbH, Transposagen Biopharmaceuticals, Inc., SAGE Labs, Biomedical Research Models, Inc., and Covance, Inc.
The firms are leveraging numerous organic and inorganic strategies to increase their market share in the global rat model market. They are getting into collaborations with small companies, which are operational in this industry and other CROs to increase their revenues.
One of them are as follows:
On April 2016, Charles River Laboratories and BioMotiv entered into a Strategic Partnership. By this agreement, Charles River Laboratories capability to enable the drug research process from discovery by safety testing has no comparison in the industry, which will help BioMotiv in drug discovery & development activities.
1. METHODOLOGY & SCOPE
1.1. RESEARCH METHODOLOGY
1.2. RESEARCH SCOPE & ASSUMPTIONS
1.3. LIST OF DATA SOURCES
2. EXECUTIVE SUMMARY
2.1. GLOBAL RAT MODEL INDUSTRY - MARKET SUMMARY & KEY BUYING CRITERIA
2.2. GLOBAL RAT MODEL INDUSTRY OUTLOOK
2.3. SEGMENTATION ANALYSIS
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022
2.5. RAT MODEL INDUSTRY VALUE CHAIN ANALYSIS
2.6. VENDOR LANDSCAPE
3. INDUSTRIAL RAT MODEL MARKET DYNAMICS
3.1.1. MARKET DRIVER ANALYSIS
18.104.22.168. INNOVATIONS IN GENE EDITING TOOLS SET TO INCREASE THE DEMAND
22.214.171.124. BENEFITS OF RATS OVER MICE
126.96.36.199. INVESTMENTS AND PERMISSIONS
188.8.131.52. PERSONALIZED MEDICINE TO BOOST THE DEMAND
184.108.40.206. RISING R&D ACTIVITIES OF BIOTECH AND PHARMACEUTICAL INDUSTRIES
220.127.116.11. GROWTH OF PRE-CLINICAL RESEARCH ACTIVITIES
3.1.2. MARKET RESTRAINT ANALYSIS
18.104.22.168. SUBSTITUTE METHODS TO ANIMAL TESTING
22.214.171.124. INNOVATIONS IN ZEBRAFISH MODEL DEVELOPMENT
3.1.3. KEY OPPORTUNITIES
126.96.36.199. RISING APPLICATION IN BASIC & APPLIED RESEARCH FOR DRUG DELIVERY & DEVELOPMENT
3.1.4. KEY CHALLENGES
188.8.131.52 STRINGENT REGULATORY FRAMEWORK
4. INDUSTRY ANALYSIS
4.1. GLOBAL RAT MODEL INDUSTRY– PORTER’S FIVE FORCES MODEL
4.2. GLOBAL RAT MODEL INDUSTRY– PESTEL ANALYSIS
4.3. GLOBAL RAT MODEL– GAP ANALYSIS
5. GLOBAL RAT MODEL BY APPLICATION 2012-2022 ($ MILLION)
5.1. GLOBAL RAT MODEL MARKET BY IMMUNOLOGY AND INFLAMMATION 2012-2022 ($ MILLION)
5.2. GLOBAL RAT MODEL MARKET BY ONCOLOGY 2012-2022 ($ MILLION)
5.3. GLOBAL RAT MODEL MARKET BY TOXICOLOGY 2012-2022 ($ MILLION)
5.4. GLOBAL RAT MODEL MARKET BY DIABETES 2012-2022 ($ MILLION)
5.5. GLOBAL RAT MODEL MARKET BY OTHER APPLICATIONS 2012-2022 ($ MILLION)
6. GLOBAL RAT MODEL BY TYPE 2012-2022 ($ MILLION)
6.1. GLOBAL RAT MODEL MARKET BY OUTBRED RATS 2012-2022 ($ MILLION)
6.2. GLOBAL RAT MODEL MARKET BY CONDITIONED/SURGICALLY MODIFIED RATS 2012-2022 ($ MILLION)
6.3. GLOBAL RAT MODEL MARKET BY INBRED RATS 2012-2022 ($ MILLION)
6.4. GLOBAL RAT MODEL MARKET BY HYBRID/CONGENIC RATS 2012-2022 ($ MILLION)
6.5. GLOBAL RAT MODEL MARKET BY KNOCKOUT/GENETICALLY ENGINEERED RATS 2012-2022 ($ MILLION)
6.6. GLOBAL RAT MODEL MARKET BY IMMUNODEFICIENT RATS 2012-2022 ($ MILLION)
7. GLOBAL RAT MODEL BY SERVICE 2012-2022 ($ MILLION)
7.1. GLOBAL RAT MODEL MARKET BY GENETIC TESTING 2012-2022 ($ MILLION)
7.2. GLOBAL RAT MODEL MARKET BY REDERIVATION 2012-2022 ($ MILLION)
7.3. GLOBAL RAT MODEL MARKET BY QUARANTINE 2012-2022 ($ MILLION)
7.4. GLOBAL RAT MODEL MARKET BY BREEDING 2012-2022 ($ MILLION)
7.5. GLOBAL RAT MODEL MARKET BY CRYOPRESERVATION 2012-2022 ($ MILLION)
7.6. GLOBAL RAT MODEL MARKET BY OTHER SERVICES 2012-2022 ($ MILLION)
8. GLOBAL RAT MODEL BY TECHNOLOGY 2012-2022 ($ MILLION)
8.1. GLOBAL RAT MODEL MARKET BY MICROINJECTION 2012-2022 ($ MILLION)
8.2. GLOBAL RAT MODEL MARKET BY EMBRYONIC STEM CELLS 2012-2022 ($ MILLION)
8.3. GLOBAL RAT MODEL MARKET BY NUCLEAR TRANSFERASE 2012-2022 ($ MILLION)
8.4. GLOBAL RAT MODEL MARKET BY NUCLEAR OTHERS 2012-2022 ($ MILLION)
9. GLOBAL RAT MODEL INDUSTRY REGIONAL OUTLOOK 2012-2022 ($ MILLION)
9.1. NORTH AMERICA
9.3. ASIA PACIFIC
184.108.40.206. SOUTH KOREA
9.4. MIDDLE EAST & AFRICA
9.5. CENTRAL &SOUTH AMERICA
10. COMPETITIVE LANDSCAPE
10.1.1. COMPANY OVERVIEW
10.1.1.1. SCOT ANALYSIS
10.1.1.2. PRODUCT BENCHMARKING
10.1.2. STRATEGIC INITIATIVES
10.2. BIOBSERVE GMBH
10.2.1. COMPANY OVERVIEW
10.2.2. SCOT ANALYSIS
10.2.3. PRODUCT BENCHMARKING
10.2.4. STRATEGIC INITIATIVES
10.3. BIOMEDICAL RESEARCH MODELS, INC.
10.3.1. COMPANY OVERVIEW
10.3.2. SCOT ANALYSIS
10.3.3. PRODUCT BENCHMARKING
10.3.4. STRATEGIC INITIATIVES
10.4. CHARLES RIVER LABORATORIES
10.4.1. COMPANY OVERVIEW
10.4.2. SCOT ANALYSIS
10.4.3. PRODUCT BENCHMARKING
10.4.4. STRATEGIC INITIATIVES
10.5. COVANCE, INC.
10.5.1. COMPANY OVERVIEW
10.5.2. SCOT ANALYSIS
10.5.3. PRODUCT BENCHMARKING
10.5.4. STRATEGIC INITIATIVES
10.6.1. COMPANY OVERVIEW
10.6.2. SCOT ANALYSIS
10.6.3. PRODUCT BENCHMARKING
10.6.4. STRATEGIC INITIATIVES
10.7. GENOWAY S.A.
10.7.1. COMPANY OVERVIEW
10.7.2. SCOT ANALYSIS
10.7.3. PRODUCT BENCHMARKING
10.7.4. STRATEGIC INITIATIVES
10.8. HARLAN LABORATORIES, INC.
10.8.1. COMPANY OVERVIEW
10.8.2. SCOT ANALYSIS
10.8.3. PRODUCT BENCHMARKING
10.8.4. STRATEGIC INITIATIVES
10.9. JANVIER LABS
10.9.1. COMPANY OVERVIEW
10.9.2. SCOT ANALYSIS
10.9.3. PRODUCT BENCHMARKING
10.9.4. STRATEGIC INITIATIVES
10.10. SAGE LABS
10.10.1. COMPANY OVERVIEW
10.10.2. SCOT ANALYSIS
10.10.3. PRODUCT BENCHMARKING
10.10.4. STRATEGIC INITIATIVES
10.11. TACONIC BIOSCIENCES, INC.
10.11.1. COMPANY OVERVIEW
10.11.2. SCOT ANALYSIS
10.11.3. PRODUCT BENCHMARKING
10.11.4. STRATEGIC INITIATIVES
10.12. TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
10.12.1. COMPANY OVERVIEW
10.12.2. SCOT ANALYSIS
10.12.3. PRODUCT BENCHMARKING
10.12.4. STRATEGIC INITIATIVES
10.13. TRANSVIRAGEN, INC.
10.13.1. COMPANY OVERVIEW
10.13.2. SCOT ANALYSIS
10.13.3. PRODUCT BENCHMARKING
10.13.4. STRATEGIC INITIATIVES